News for MDGL Stock

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting® Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom) Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates Madrigal Statement on the Passing of Dr. Stephen Harrison Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering Madrigal Pharmaceuticals Announces Proposed Public Offering Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Announces Additions to Its Leadership Team Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering Madrigal Pharmaceuticals Announces Proposed Public Offering Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™ Madrigal Pharmaceuticals Supports International NASH Day on June 8 Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Madrigal Pharmaceuticals Supports International NASH Day on June 9 Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9 Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences Positive Resmetirom Data from Completed Open-Label Portion of Phase 3 MAESTRO-NAFLD-1 Clinical Study Presented at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® Digital Experience 2021 Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results Madrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021 Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference Madrigal Pharmaceuticals to Present at RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8:00 a.m. ET Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-We Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 We Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020 Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights